PMV Pharmaceuticals, Inc. (PMVP)Healthcare | Biotechnology | Princeton, United States | NasdaqGS
1.28 USD
+0.04
(3.226%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.30 +0.02 (1.555%) ⇧ (July 13, 2026, 5:03 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:54 a.m. EDT
The investment case here is severely compromised by a four-year structural decline where the stock has lost 96% of its value, dropping from nearly $35 in 2021 to just $1.24 today. While the analyst consensus is aggressively bullish with a $4.00 target, the underlying reality is stark: the company is burning through cash with negative free cash flow and negative returns on equity, and it has no dividend to provide any income cushion. The recent price action shows a fragile, choppy recovery that hasn't yet broken key moving averages, suggesting the market remains skeptical despite the hype. The options market confirms this asymmetry; traders are buying deep out-of-the-money calls hoping for a miracle, while offering almost no protection against further ruin. Until the company demonstrates a path to profitability or a definitive catalyst that resolves the funding concerns mentioned in recent headlines, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.133106 |
| AutoTheta | 0.137140 |
| AutoARIMA | 0.139309 |
| AutoETS | 0.141104 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 14.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.335 |
| Excess Kurtosis | -1.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.333 |
| Market Cap | 68,264,664 |
| Forward P/E | -1.17 |
| Beta | 1.33 |
| Website | https://www.pmvpharma.com |
As of July 11, 2026, 3:54 a.m. EDT: Speculators are positioning exclusively for upside exposure via calls, with significant open interest concentrated at the $2.50 strike (roughly double the current price) and further out at $5.00. This indicates a speculative bet on a binary event or recovery rather than hedging against downside risk, as there is virtually no put volume or open interest to protect against further declines.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08148146 |
| Address1 | 400 Alexander Park Drive |
| Address2 | Suite 301 |
| All Time High | 63.22 |
| All Time Low | 0.81 |
| Ask | 1.58 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 248,990 |
| Average Daily Volume3 Month | 353,500 |
| Average Volume | 353,500 |
| Average Volume10Days | 248,990 |
| Beta | 1.326 |
| Bid | 0.9504 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.649 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.28 |
| Current Ratio | 11.144 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.345 |
| Day Low | 1.24 |
| Debt To Equity | 0.333 |
| Display Name | PMV Pharmaceuticals |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -83,531,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.299 |
| Enterprise Value | -24,991,340 |
| Eps Current Year | -1.515 |
| Eps Forward | -1.09333 |
| Eps Trailing Twelve Months | -1.48 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2391 |
| Fifty Day Average Change | 0.040899992 |
| Fifty Day Average Change Percent | 0.033007823 |
| Fifty Two Week Change Percent | -8.148146 |
| Fifty Two Week High | 1.88 |
| Fifty Two Week High Change | -0.6 |
| Fifty Two Week High Change Percent | -0.31914896 |
| Fifty Two Week Low | 1.02 |
| Fifty Two Week Low Change | 0.26 |
| Fifty Two Week Low Change Percent | 0.25490195 |
| Fifty Two Week Range | 1.02 - 1.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,040,600,000 |
| Float Shares | 43,135,799 |
| Forward Eps | -1.09333 |
| Forward P E | -1.1707352 |
| Free Cashflow | -46,588,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 54 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03348 |
| Held Percent Institutions | 0.67749 |
| Implied Shares Outstanding | 53,331,766 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey. |
| Long Name | PMV Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 68,264,664 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_259910295 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -78,344,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 66,131,389 |
| Number Of Analyst Opinions | 4 |
| Open | 1.24 |
| Operating Cashflow | -74,990,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 609 642 6670 |
| Post Market Change | 0.019900084 |
| Post Market Change Percent | 1.554694 |
| Post Market Price | 1.2999 |
| Post Market Time | 1,783,976,608 |
| Previous Close | 1.24 |
| Price Eps Current Year | -0.84488446 |
| Price Hint | 4 |
| Price To Book | 0.77622795 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.884 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 3.2258 |
| Regular Market Day High | 1.345 |
| Regular Market Day Low | 1.24 |
| Regular Market Day Range | 1.24 - 1.345 |
| Regular Market Open | 1.24 |
| Regular Market Previous Close | 1.24 |
| Regular Market Price | 1.28 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 887,847 |
| Return On Assets | -0.39141998 |
| Return On Equity | -0.63162 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 53,331,766 |
| Shares Percent Shares Out | 0.0546 |
| Shares Short | 2,910,642 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,255,236 |
| Short Name | PMV Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.056500003 |
| Short Ratio | 9.64 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PMVP |
| Target High Price | 5.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 93,549,000 |
| Total Cash Per Share | 1.754 |
| Total Debt | 293,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.300375 |
| Two Hundred Day Average Change | -0.020375013 |
| Two Hundred Day Average Change Percent | -0.015668567 |
| Type Disp | Equity |
| Volume | 887,847 |
| Website | https://www.pmvpharma.com |
| Zip | 8,540 |